Ratings Indaptus Therapeutics, Inc.

Equities

INDP

US45339J1051

Delayed Nasdaq 02:44:38 2024-03-28 pm EDT 5-day change 1st Jan Change
2.22 USD -10.84% Intraday chart for Indaptus Therapeutics, Inc. -2.20% +26.14%

Strengths

  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
+26.14% 21.26M - -
+9.21% 45.97B
B
+52.73% 43.93B
A
+7.24% 42.34B
B-
-8.78% 28.27B
C
+18.20% 27.18B
B-
-21.28% 19.44B
B
+14.37% 13.83B
C+
+32.31% 12.4B
C+
+5.53% 11.45B
B+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
-
Profitability
-
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
-
4 months Revenue revision
-
7 days Revenue revision
-
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes